
NASDAQHealthcareDrug Manufacturers - Specialty & Generic
最新データ
$6.45
+$0.02 · +0.31%
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
前日終値
$6.45
+$0.02 · +0.31%
日中の時刻はETです。市場データは遅延する場合があります。
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
日中レンジ
現在 $6.45
52週レンジ
現在 $6.45
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
47
適正価値
センチメント
52
まちまち
リスク
68
高リスク
モメンタム
26
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization that serves customers in the United States, Belgium, the Netherlands, and internationally. It provides services in the development, manufacture, aseptic fill, and finish of formulations and highly viscous sterile injectable pharmaceutical drug or medical device products in syringes, vials, and cartridges in various modalities. The company also manufactures and sells pharmaceutical-grade hyaluronic acid in bulk form, as well as for use in formulated and filled syringes and vials for injectable products used in treating various medical conditions and procedures, including ophthalmic and orthopedic applications. In addition, it offers product development services, including analytical method development and validation, formulation development, sterile filtration, process scale-up, pilot studies, stability studies, process validation, and materials production for clinical studies. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.
日中レンジ
現在 $6.45
52週レンジ
現在 $6.45
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標(USD) | 2026年度 | 2025年度 | 2024年度 | 2023年度 | 2022年度 |
|---|---|---|---|---|---|
| 売上高 | 1.29億 USD | 1.29億 USD | 1.28億 USD | 1.03億 USD | 1.11億 USD |
| 売上原価 | 8885.49万 USD | 8856.9万 USD | 8641.1万 USD | 7528.4万 USD | 7220.4万 USD |
| 粗利益 | 4060.97万 USD | 4029.8万 USD | 4185万 USD | 2798.5万 USD | 3906.6万 USD |
| 研究開発 | 850.3万 USD | 825.8万 USD | 857.5万 USD | 873.6万 USD | 783.9万 USD |
| 販売・一般管理 | 3335.49万 USD | 4404.6万 USD | 4046.3万 USD | 3896.9万 USD | 3465.9万 USD |
| 営業費用 | 4186.63万 USD | 5754.3万 USD | 5069.4万 USD | 4978.1万 USD | 5085.7万 USD |
| 受取利息 | — | — | — | 6.8万 USD | 8.1万 USD |
| 支払利息 | −221.4万 USD | 2183.5万 USD | 1809万 USD | 1764.9万 USD | 1555.1万 USD |
| 減価償却費と償却費 | 949.89万 USD | 802.7万 USD | 795.4万 USD | 1317.7万 USD | 1806.1万 USD |
| 営業利益 | −125.66万 USD | −1724.5万 USD | −884.4万 USD | −2179.6万 USD | −1179.1万 USD |
| 純利益 | −3079.03万 USD | −3871.7万 USD | 1201.3万 USD | −9956.3万 USD | −1.17億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM479.33万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Morningstar Total Stock Market ETFVTI366.66万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF194.19万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO72.94万0.00%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC57.81万0.04%13.17億 USD0.60%$183+0.11%
Vanguard Russell 2000 Value ETFVTWV11.06万0.01%14億 USD0.06%$185.81-0.13%
iShares Russell 2500 ETFSMMD10.09万0.00%40.62億 USD0.23%$86.29+0.38%
Global X - Russell 2000 ETFRSSL8.78万0.01%14.19億 USD0.08%$109.09+0.21%
iShares Russell 2000 ETFIWM
Vanguard Morningstar Total Stock Market ETFVTI
Vanguard Extended Market ETFVXF
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Vanguard Russell 2000 Value ETFVTWV
iShares Russell 2500 ETFSMMD
Global X - Russell 2000 ETFRSSLAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。